RxDoctor Payments Data

William Packard, MD

Psychiatry · Bryn Mawr, PANPI 1730293796

Payments from drug & device makers

$900in general payments, 2019–2025

Across 44 payments — averaging $20.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$438
  • Alkermes, Inc.$194
  • Vanda Pharmaceuticals Inc.$64
  • Sunovion Pharmaceuticals Inc.$46
  • Avanir Pharmaceuticals, Inc.$38
  • Neurocrine Biosciences, Inc.$32
  • plus $87 from 4 others

What the payments were for

  • Food & beverage$900100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$900 in reported general payments places this provider in the 75th percentile of 1,838 psychiatry providers in Pennsylvania.

See all psychiatry providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$11,646
Medicare patients
65
Services billed
179

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate20$175,244
Invega SustennaPaliperidone Palmitate37$140,640
VraylarCariprazine Hcl74$110,421
Abilify MaintenaAripiprazole38$105,694
AustedoDeutetrabenazine16$99,722
RexultiBrexpiprazole47$69,092
Aripiprazole284$33,512
TrintellixVortioxetine Hydrobromide25$18,083
AristadaAripiprazole Lauroxil12$16,735
Quetiapine Fumarate246$8,184
Divalproex Sodium ErDivalproex Sodium58$5,540
Hydroxyzine Pamoate167$5,128
Duloxetine Hcl135$4,933
Buspirone Hcl212$4,100
Chlorpromazine Hcl12$3,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$32$175,24420 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$438$174,78685 claims
Johnson & JohnsonInvega Sustenna$12$140,64037 claims
AbbVieVraylar$27$110,42174 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$27$18,08325 claims
Alkermes, Inc.Aristada$194$16,73512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,838 psychiatry providers in Pennsylvania.

Other psychiatry in Bryn Mawr

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →